Intellia Therapeutics, Inc.

Developing curative genome editing treatments

Founded 2014

Cambridge, United States 488 employees IPO Total: $1.40B Biotechnology, Health Care +1

Intellia Therapeutics, Inc., founded in 2014, is a pioneering clinical-stage biopharmaceutical company headquartered in the United States. Specializing in the Biotechnology, Health Care, and Health and Wellness industries, Intellia's slogan, "Developing curative genome editing treatments," underscores its mission to transform medicine by employing CRISPR and proprietary gene-editing technologies.

The company's strategic focus is on addressing and potentially curing severe diseases by tackling their root causes. Intellia's deep expertise across scientific, technical, and clinical domains allows it to develop a range of therapeutic solutions with the potential to revolutionize patient care on a global scale.

Intellia's recent financial milestone was a $43.00M Post IPO Equity investment on 01 May 2026 from Ark Invest, reinforcing confidence in its innovative approach and promising therapeutic pipelines. This infusion of capital supports Intellia's continued research and development, positioning it as a compelling opportunity for investors in the biotech sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$43.00M	1	Ark Invest	01 May 2026
Post-IPO Equity	$1.33M	1	Ark Invest	01 Dec 2025
Post-IPO Equity	$300.00M	-		01 Dec 2022
Post-IPO Equity	$600.00M	-		01 Jun 2021
Grant	Undisclosed	1	Bill & Melinda Gates Foundation	01 Nov 2020
Post-IPO Equity	$115.00M	-		01 Jun 2020
Post-IPO Equity	$150.00M	-		01 Nov 2017
IPO	$108.00M	-		01 May 2016
Series B	$70.00M	2	OrbiMed, Foresite Capital	01 Sep 2015
Series A	$15.00M	1	Berkeley Ventures	01 Dec 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

$43.00M

Ark Invest

01 May 2026

Post-IPO Equity

$1.33M

Ark Invest

01 Dec 2025

Post-IPO Equity

$300.00M

01 Dec 2022

Post-IPO Equity

$600.00M

01 Jun 2021

Grant

Undisclosed

Bill & Melinda Gates Foundation

01 Nov 2020

Post-IPO Equity

$115.00M

01 Jun 2020

Post-IPO Equity

$150.00M

01 Nov 2017

IPO

$108.00M

01 May 2016

Series B

$70.00M

OrbiMed, Foresite Capital

01 Sep 2015

Series A

$15.00M

Berkeley Ventures

01 Dec 2014

FAQ About Intellia Therapeutics, Inc.

Developing curative genome editing treatments

Intellia Therapeutics, Inc. was founded in 2014.

Intellia Therapeutics, Inc. is headquartered in Cambridge, United States.

Intellia Therapeutics, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Gene Editing, CRISPR-Cas9, Biopharmaceutical and Clinical-stage. Its customers include Patients with Severe Diseases, Healthcare Professionals and Biotechnology Researchers.

Intellia Therapeutics, Inc. has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.

Intellia Therapeutics, Inc. has approximately 488 employees.

Intellia Therapeutics, Inc. has completed 10 funding rounds, raising a total of $1.40B. The latest funding stage is IPO.

Intellia Therapeutics, Inc. offers: Development of Genome Editing Therapies, Clinical Research and Trials, Patient Support and Education, Scientific Research and Publications, Treatment Commercialization.

Top alternatives and competitors to Intellia Therapeutics, Inc. include Orchard Therapeutics - U.S., bluebird bio, Spark Therapeutics, Inc., Caribou Biosciences, 克睿基因 Cure Genetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Intellia Therapeutics, Inc. and Orchard Therapeutics - U.S. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Intellia Therapeutics, Inc.

General Information

Discover More

About Intellia Therapeutics, Inc.

Services & Products

Target Customers

Funding Rounds & Investors (10)

Intellia Therapeutics, Inc. Alternatives & Competitors

FAQ About Intellia Therapeutics, Inc.